GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDL BioPharma Inc (NAS:PDLI) » Definitions » Gross Profit

PDL BioPharma (PDL BioPharma) Gross Profit : $15.62 Mil (TTM As of Jun. 2020)


View and export this data going back to 1992. Start your Free Trial

What is PDL BioPharma Gross Profit?

PDL BioPharma's gross profit for the three months ended in Jun. 2020 was $2.57 Mil. PDL BioPharma's gross profit for the trailing twelve months (TTM) ended in Jun. 2020 was $15.62 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. PDL BioPharma's gross profit for the three months ended in Jun. 2020 was $2.57 Mil. PDL BioPharma's Revenue for the three months ended in Jun. 2020 was $5.21 Mil. Therefore, PDL BioPharma's Gross Margin % for the quarter that ended in Jun. 2020 was 49.36%.

PDL BioPharma had a gross margin of 49.36% for the quarter that ended in Jun. 2020 => Durable competitive advantage


PDL BioPharma Gross Profit Historical Data

The historical data trend for PDL BioPharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDL BioPharma Gross Profit Chart

PDL BioPharma Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 554.25 209.83 271.78 147.31 1.14

PDL BioPharma Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.53 29.13 -19.22 3.14 2.57

Competitive Comparison of PDL BioPharma's Gross Profit

For the Biotechnology subindustry, PDL BioPharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDL BioPharma's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDL BioPharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where PDL BioPharma's Gross Profit falls into.



PDL BioPharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

PDL BioPharma's Gross Profit for the fiscal year that ended in Dec. 2019 is calculated as

Gross Profit (A: Dec. 2019 )=Revenue - Cost of Goods Sold
=54.757 - 53.619
=1.14

PDL BioPharma's Gross Profit for the quarter that ended in Jun. 2020 is calculated as

Gross Profit (Q: Jun. 2020 )=Revenue - Cost of Goods Sold
=5.211 - 2.639
=2.57

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.62 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

PDL BioPharma's Gross Margin % for the quarter that ended in Jun. 2020 is calculated as

Gross Margin % (Q: Jun. 2020 )=Gross Profit (Q: Jun. 2020 ) / Revenue (Q: Jun. 2020 )
=(Revenue - Cost of Goods Sold) / Revenue
=2.57 / 5.211
=49.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


PDL BioPharma  (NAS:PDLI) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

PDL BioPharma had a gross margin of 49.36% for the quarter that ended in Jun. 2020 => Durable competitive advantage


PDL BioPharma Gross Profit Related Terms

Thank you for viewing the detailed overview of PDL BioPharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


PDL BioPharma (PDL BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
932 Southwood Boulevard, Incline Villiage, NV, USA, 89451
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.
Executives
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
John Peter Mclaughlin director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Dominique Monnet officer: President and CEO C/O ALEXION PHARMACEUTICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Christopher Lewis Stone officer: VP, Gen. Counsel & Secretary 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Alan Lee Bazaar director 9 BEDFORD ROAD, KATONAH NY 10536
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Edward Imbrogno officer: VP Finance, CAO and Acting CFO 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Jill M. Jene officer: VP, Business Development 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Harold E Selick director
Samuel R Saks director 3180 PORTER DRIVE, PALO ALTO CA 94304
Paul W Sandman director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Peter S Garcia officer: Vice President, CFO ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jody S Lindell director 2536 FILLMORE ST., SAN FRANCISCO CA 94115
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010